BioLineRx Ltd.

3.36
-0.13 (-3.72%)
At close: Feb 07, 2025, 3:59 PM
3.40
1.19%
After-hours Feb 07, 2025, 04:37 PM EST
undefined%
Bid 3.4
Market Cap 12.50M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -12
PE Ratio (ttm) -0.28
Forward PE n/a
Analyst Buy
Ask 3.48
Volume 126,278
Avg. Volume (20D) 7,853,573
Open 3.46
Previous Close 3.49
Day's Range 3.26 - 3.49
52-Week Range 0.08 - 4.44
Beta undefined

About BLRX

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in pat...

Industry Biotechnology
Sector Healthcare
IPO Date Jul 27, 2011
Employees 79
Stock Exchange NASDAQ
Ticker Symbol BLRX

Analyst Forecast

According to 2 analyst ratings, the average rating for BLRX stock is "Buy." The 12-month stock price forecast is $220, which is an increase of 6447.62% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

BioLineRx Ltd. is scheduled to release its earnings on Mar 25, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago
-16.8%
BioLineRx shares are trading lower after the compa... Unlock content with Pro Subscription
1 month ago
-40.82%
BioLineRx shares are trading lower after the company announced a $10 million registered direct offering.